Meta-Analysis of Anlotinib and PD-1/PD-L1 Inhibitors for Solid Tumors
by Chen Wang·Updated 3mo ago
1.8 MB1files
Available on 1 platform
Sign in to view source links and access this dataset
Description
26 studies involving 3,263 patients were analyzed, covering data from database inception to November 2025. The dataset compiles efficacy and safety metrics from randomized controlled trials, cohort studies, and single-arm studies. It reports outcomes such as Objective Response Rate, Disease Control Rate, Overall Survival, and adverse reactions for combination therapy versus control groups.
Use Cases
Compare the pooled Objective Response Rate (ORR) and Disease Control Rate (DCR) between combination and control therapy groups across 26 studies.
Analyze the hazard ratios (HR) for Overall Survival (OS) and Progression Free Survival (PFS) to quantify treatment benefit from anlotinib combined with PD-1/PD-L1 inhibitors.
Assess the relative risk (RR) of specific adverse reactions like fatigue and hypoalbuminemia reported in the meta-analysis results.
Evaluate the network meta-analysis finding indicating superior efficacy for the specific combination of anlotinib and TQB2450.
Strengths
Analysis is based on 26 identified studies encompassing 3,263 patient records.
Reports specific statistical measures including risk ratios (RR) and hazard ratios (HR) with 95% confidence intervals for key outcomes.
Data was gathered from multiple authoritative biomedical databases: PubMed, Web of Science, Embase, and Cochrane Library.
Limitations
The underlying data is aggregated from published studies; original patient-level data is not available.
As a meta-analysis, findings are subject to the biases and heterogeneity of the included primary studies.
The dataset is a 1.8 MB DOCX document, limiting direct computational analysis and requiring manual extraction of tabular data.
Provenance
Source
PubMed, Web of Science, Embase, and Cochrane Library databases.
Collection Method
Systematic review and meta-analysis of randomized controlled trials, cohort studies, and single-arm studies.
Time Range
From database inception to November 2025.
Freshness
Literature search covered studies up to November 2025; the dataset itself was last updated on 2026-03-24.
Data is presented in a DOCX file format; statistical results are embedded in text and tables, requiring extraction for quantitative reuse. Licensed under CC BY 4.0.